Skip to main content
GOVX
NASDAQ Life Sciences

GeoVax Raises $3.6M via Warrant Inducement, Issues 11.4M New Warrants

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.6
Mkt Cap
$5.313M
52W Low
$0.59
52W High
$19.205
52W Position info
1.7% above low
Off High info
97% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

GOVX is trading near its 52-week low of $0.59 (1.7% above the low).

Summary

GeoVax Labs raised $3.65 million by inducing an existing investor to exercise warrants, issuing 11.4 million new warrants at $0.64 per share in return. The cash extends the company's runway, but the new warrants create substantial potential dilution pending stockholder approval.


Key Events · Financing and Capital Events · GOVX

  • Warrant Inducement Raises $3.65M

    Armistice Capital Master Fund Ltd. exercised 5,697,628 existing warrants for approximately $3,646,482 in gross proceeds, before fees.

  • 11.4M New Warrants Issued

    GeoVax issued 11,395,256 new warrants at $0.64 per share, exercisable only after stockholder approval, expiring five years from approval date.

  • Stockholder Approval Required by Oct 29

    Company must hold a stockholder meeting by October 29, 2026 to approve the new warrant exercise; if not obtained, meetings repeat every 90 days.

  • Financial Advisor Fees

    A.G.P./Alliance Global Partners receives 7.0% of gross proceeds plus up to $40,000 in legal expense reimbursement.


Analysis · GOVX · Life Sciences

GeoVax Labs entered into a warrant inducement agreement with Armistice Capital Master Fund Ltd. to exercise 5,697,628 existing warrants for approximately $3.65 million in gross proceeds. In exchange, the company issued 11,395,256 new warrants at an exercise price of $0.64 per share, exercisable only after stockholder approval. The transaction provides critical near-term cash for a company that reported only $3.1 million in cash as of July 27, 2026, funding operations only into September 2026. However, the new warrants represent significant potential future dilution, and the company must obtain stockholder approval by October 29, 2026, adding execution risk. The deal also includes a 7.0% financial advisor fee and a $40,000 expense reimbursement to A.G.P./Alliance Global Partners.

How filings like this one have moved

In the 30 days to Sep 11, 2026, 36.1% of the 1758 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.05%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GOVX was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.59 to $19.21. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GOVX - Latest Insights

GOVX
Sep 10, 2026, 4:41 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.460
Real-time Price: $0.4581 info
Change: -$0.0019 (-0.41%) info
Market Cap: $4.233M info
GOVX
Sep 10, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.4655
Real-time Price: $0.4581 info
Change: -$0.0074 (-2%) info
Market Cap: $4.233M info
GOVX
Sep 09, 2026, 9:00 AM EDT
Source: EQS
Importance Score:
7
Price at Filing: $0.4818
Real-time Price: $0.4581 info
Change: -$0.0237 (-5%) info
Market Cap: $4.233M info
GOVX
Aug 31, 2026, 4:41 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $0.619
Real-time Price: $0.4581 info
Change: -$0.1609 (-26%) info
Market Cap: $4.233M info
GOVX
Aug 28, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.614
Real-time Price: $0.4581 info
Change: -$0.1559 (-25%) info
Market Cap: $4.233M info